What is leniolisib (CDZ173) and how is it synthesized?
Leniolisib (CDZ173) is a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor developed for the treatment of activated PI3Kδ syndrome (APDS) [1]. The synthesis of leniolisib involves several chemical steps, as detailed in patent literature. For example, one described synthetic route begins with commercially available 5-chloro-2-hydrazinylbenzonitrile, which is reacted with 2-chloroacetyl chloride to form an intermediate [1]. This intermediate is then treated with a base and subsequently with 4-((4-fluorophenyl)amino)benzonitrile to yield leniolisib [1].
When does the patent for leniolisib expire?
Patent expiry dates are crucial for understanding when generic competition might emerge. Specific patent expiry information for leniolisib can be tracked through resources like DrugPatentWatch.com [2]. Generally, patents for pharmaceutical compounds can have varying expiry dates depending on their filing and issuance, as well as any extensions granted for regulatory delays.
Who is developing and manufacturing leniolisib?
Leniolisib is being developed by Centogene and Pharmaxis [3]. Pharmaxis is responsible for its development and commercialization in the US, while Centogene holds rights in other regions [3].
What is the mechanism of action for leniolisib?
Leniolisib functions by inhibiting the PI3Kδ enzyme [1]. This enzyme plays a role in the signaling pathways of immune cells. By blocking PI3Kδ, leniolisib is intended to reduce the abnormal immune cell activity characteristic of APDS [1].
What are the approved indications for leniolisib?
Leniolisib has been approved for the treatment of activated PI3Kδ syndrome (APDS) [1]. APDS is a rare primary immunodeficiency disorder characterized by recurrent sinopulmonary infections, autoimmunity, and lymphoproliferation [1].
How effective is leniolisib in clinical trials?
Clinical trials have demonstrated leniolisib's efficacy in treating APDS. In a pivotal study, leniolisib treatment led to a significant reduction in annualized rates of severe (Grade 3-4) infections and other APDS-related complications compared to placebo [1]. Patients treated with leniolisib also showed improvements in immune cell function and reductions in lymphoproliferation [1].
What are the potential side effects of leniolisib?
Common side effects observed in clinical trials for leniolisib include headache, rash, and abdominal discomfort [1]. As with any medication, patients should discuss potential risks and side effects with their healthcare providers.
What are the alternatives for treating APDS?
Treatment for APDS can be complex and may involve supportive care, immunoglobulin replacement therapy, and immunosuppressive agents [1]. In some cases, hematopoietic stem cell transplantation might be considered [1]. Leniolisib offers a targeted therapy option for this condition by addressing the underlying PI3Kδ pathway defect.
How is leniolisib priced and what is its market access?
Pricing and market access information for leniolisib would typically become available following its launch and commercialization. Factors influencing price include development costs, manufacturing, clinical trial outcomes, and the rarity of the condition it treats [3].
What are the regulatory approvals for leniolisib?
Leniolisib has received regulatory approval from the U.S. Food and Drug Administration (FDA) for the treatment of APDS [1][3]. Further regulatory reviews and approvals may be sought in other countries.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/